IL6 and non-small cell lung carcinoma: Recent research indicates EGFR-TKIs trigger NF-κB activation, leading to the emergence of EGFR-TKIs resistance via several pathways such as activation-induced cytidine deaminase, Akt, and interleukin-6 (IL-6)/JAK2/STAT3 in NSCLC (62).